

Ivo N Van Schaik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6767177/publications.pdf>

Version: 2024-02-01

40
papers

1,218
citations

567281

15
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

1402
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoglobulin for multifocal motor neuropathy. The Cochrane Library, 2022, 2022, CD004429.	2.8	6
2	Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2022, 145, 1641-1652.	7.6	16
3	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	3.1	3
4	Assessment of disability in idiopathic inflammatory myopathy: a call for linearity. Rheumatology, 2022, 61, 3420-3426.	1.9	1
5	Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study. Rheumatology, 2022, 62, 300-309.	1.9	6
6	Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology, 2021, 60, 1784-1792.	1.9	25
7	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 839-850.	2.5	2
8	OptimisAtion of Diagnostic Accuracy in idioPathic inflammaTory myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy. BMJ Open, 2021, 11, e053594.	1.9	1
9	Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology, 2020, 94, e62-e74.	1.1	51
10	Cognitive functioning and depressive symptoms in Fabry disease: A followâ€up study. Journal of Inherited Metabolic Disease, 2020, 43, 1070-1081.	3.6	8
11	Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain. Orphanet Journal of Rare Diseases, 2020, 15, 28.	2.7	19
12	The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease. JIMD Reports, 2019, 48, 53-59.	1.5	7
13	Muscle weakness in a S. pneumoniae sepsis mouse model. Annals of Translational Medicine, 2019, 7, 9-9.	1.7	4
14	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e590.	6.0	37
15	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
16	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
17	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 187-194.	3.1	59
18	Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. Journal of the Neurological Sciences, 2019, 397, 141-145.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Intravenous versus subcutaneous immunoglobulin – Authors' reply. <i>Lancet Neurology</i> , The, 2018, 17, 393-394.	10.2	0
20	Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 49-54.	3.1	15
21	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
22	046 – Efficacy and safety of intravenous immunoglobulin (IVIg) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A19.2-A19.	1.9	0
23	Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 205-216.	1.1	23
24	No association between systemic complement activation and intensive care unit-acquired weakness. <i>Annals of Translational Medicine</i> , 2018, 6, 115-115.	1.7	2
25	Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. <i>The Cochrane Library</i> , 2017, 2017, CD010369.	2.8	88
26	Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 213-218.	3.1	13
27	Diagnostic accuracy of quantitative neuromuscular ultrasound for the diagnosis of intensive care unit-acquired weakness: a cross-sectional observational study. <i>Annals of Intensive Care</i> , 2017, 7, 40.	4.6	54
28	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 345.	1.6	21
29	Assessment of intensive care unit-acquired weakness in young and old mice: An <i>E. coli</i> septic peritonitis model. <i>Muscle and Nerve</i> , 2016, 53, 127-133.	2.2	8
30	Association between i.v. thrombolysis volume and door-to-needle times in acute ischemic stroke. <i>Journal of Neurology</i> , 2016, 263, 807-813.	3.6	10
31	In Patients with an Î±-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease. <i>JIMD Reports</i> , 2015, 28, 95-103.	1.5	6
32	Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. <i>Critical Care</i> , 2015, 19, 196.	5.8	137
33	Early Prediction of Intensive Care Unit-acquired Weakness Using Easily Available Parameters: A Prospective Observational Study. <i>PLoS ONE</i> , 2014, 9, e111259.	2.5	32
34	Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe. <i>Frontiers in Immunology</i> , 2014, 5, 629.	4.8	76
35	Muscle and nerve inflammation in intensive care unit-acquired weakness: A systematic translational review. <i>Journal of the Neurological Sciences</i> , 2014, 345, 15-25.	0.6	25
36	First-line treatment for CIDP: a new piece of the puzzle. <i>Lancet Neurology</i> , The, 2012, 11, 478-479.	10.2	6

#	ARTICLE	IF	CITATIONS
37	Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 245-253.	10.2	170
38	What's new in chronic inflammatory demyelinating polyradiculoneuropathy in 2007-2008?. <i>Journal of the Peripheral Nervous System</i> , 2008, 13, 258-260.	3.1	6
39	Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 643-655.	3.1	5
40	Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. <i>Lancet Neurology</i> , The, 2002, 1, 491-498.	10.2	43